Saprisartan
Alternative Names: GR 138950Latest Information Update: 22 May 1997
At a glance
- Originator GlaxoSmithKline
- Class Antihypertensives; Heart failure therapies
- Mechanism of Action Angiotensin type 1 receptor antagonists
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
Highest Development Phases
- Discontinued Heart failure; Hypertension
Most Recent Events
- 22 May 1997 Discontinued-II for Hypertension in United Kingdom (PO)
- 05 Sep 1995 A study has been added to the pharmacodynamics section
- 10 Aug 1995 GR 138950 is now called saprisartan